Enliven Therapeutics (ELVN) Preferred Shares (2022)

Enliven Therapeutics (ELVN) reported Preferred Shares of $149.7 million for Q4 2022.

Enliven Therapeutics (ELVN) Preferred Shares (2022) Analysis & Trends

Enliven Therapeutics (ELVN) has 1 years of Preferred Shares data on file, last reported at $149.7 million in Q4 2022.

For the quarter ending Q4 2022, Preferred Shares changed N/A year-over-year to $149.7 million; the trailing twelve-month figure through Dec 2022 stood at $149.7 million (changed N/A YoY), and the FY2022 full-year result was $149.7 million, changed N/A from the prior year.
Preferred Shares was little changed at $149.7 million in Q4 2022.
In the past five years, Preferred Shares ranged from a high of $149.7 million in Q4 2022 to a low of $149.7 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Shares (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Enliven Therapeutics	3.22 Bn	3.22 Bn	-	-

Download Data

Date	Value
Dec 31, 2022	149.75 Mn